<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6210">
  <stage>Registered</stage>
  <submitdate>30/09/2014</submitdate>
  <approvaldate>30/09/2014</approvaldate>
  <nctid>NCT02254785</nctid>
  <trial_identification>
    <studytitle>Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer</studytitle>
    <scientifictitle>A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>OZM-054</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Castration-Resistant Prostatic Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - cabazitaxel
Treatment: drugs - Abiraterone
Treatment: drugs - Enzalutamide 160mg daily (oral)

Experimental: Cabazitaxel - 

Active Comparator: Abiraterone or enzalutamide - 


Treatment: drugs: cabazitaxel
Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression

Treatment: drugs: Abiraterone
Abiraterone 1000mg daily (oral) until disease progression

Treatment: drugs: Enzalutamide 160mg daily (oral)
Enzalutamide 160mg daily (oral) until disease progression

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical benefit rate - To assess and compare the clinical benefit rate in patients with mCRPC and poor prognostic factors treated with cabazitaxel or novel hormonal agents (abiraterone or enzalutamide) as initial therapy, to determine which treatment is most active in this population. Clinical benefit rate is defined as PSA or measurable radiological response of any duration or stable disease for greater than or equal to 12 weeks, in the absence of other indicators of progression.</outcome>
      <timepoint>12 weeks or more</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of treatment time to progression - To measure the treatment time before any type of progression (symptomatic, PSA, or radiological) between Arm A and Arm B</outcome>
      <timepoint>12 weeks until disease progression</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival - To measure the progression-free survival of metastatic castration-resistant prostate cancer patients following treatment with cabazitaxel or abiraterone/enzalutamide as initial therapy.</outcome>
      <timepoint>12 weeks until disease progression</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - To measure the overall survival of metastatic castration-resistant prostate cancer patients following treatment with cabazitaxel or abiraterone/enzalutamide as initial therapy.</outcome>
      <timepoint>12 weeks until 2 years after last study visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histological diagnosis of prostate adenocarcinoma.

          -  Able and willing to provide informed consent and to comply with the study procedures

          -  Age =18

          -  Evidence of metastatic disease on a chest, abdominal, or pelvic CT scan and/or bone
             scan within 6 weeks of registration

          -  Castration resistant disease defined as evidence of radiological and/or PSA
             progression despite castrate levels of testosterone (serum testosterone &lt; 50 ng/dL
             (1.7 nmol/L)). For PSA progression, there must be at least 2 sequential rises at a
             minimum of 1-week intervals. The first PSA value must be = 2. (Prostate Cancer Working
             Group 2 (PCWG2) criteria)

          -  Poor prognosis disease as defined by any of the following:

        the presence of liver metastases OR development of castration-resistance within 12 months
        of orchiectomy or commencement of LHRH antagonist/agonist for metastatic disease OR the
        presence of 4 or more of the following factors:

          -  LDH &gt; ULN

          -  ECOG Performance status (PS) 2

          -  visceral metastatic disease

          -  serum albumin less than or equal to 4 g/dL

          -  ALP &gt; ULN

          -  or &lt; 36 months from commencement of initial androgen deprivation therapy to study
             enrollment

          -  ECOG PS 0-2.

          -  Adequate end-organ function within 14 days of registration:

        Haemoglobin = 90 g/L Neutrophils = 1.5 x 109 /L Platelets = 100 x 109/L AST &lt; 1.5 x ULN ALT
        &lt; 1.5 x ULN Bilirubin = 1.0 x ULN (exceptions for Gilbert's syndrome) Creatinine = 1.5 x
        ULN

          -  At least 21 days have passed since completing radiotherapy (exception for
             radiotherapy: at least 7 days since completing a single fraction of = 800 cGy to a
             restricted field or limited-field radiotherapy to non-marrow bearing area such as an
             extremity or orbit) at the time of randomization.

          -  At least 21 days have passed since receiving any investigational agent at the time of
             registration.

          -  At least 21 days have passed since major surgery.

          -  Neuropathy = grade 1 at the time of registration.

          -  Has recovered from all therapy-related toxicity to = grade 2 (except alopecia, anemia
             and any signs or symptoms of androgen deprivation therapy) at the time of
             registration.

          -  Eligible for abiraterone acetate and/or enzalutamide as per standard of care
             practices.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Histologic evidence of small cell/neuroendocrine prostate cancer.

          -  Other chemotherapy regimen beyond one prior course of docetaxel.

          -  Previously received treatment with cabazitaxel.

          -  Received any prior next-generation anti-androgen (e.g. enzalutamide, ARN-509) or CYP
             17 inhibitors (e.g. abiraterone, TAK-700).

          -  Other condition, illness, psychiatric condition, or laboratory abnormality that may
             increase the risk associated with administration of cabazitaxel, abiraterone or
             enzalutamide, study participation, or may interfere with the interpretation of study
             results and in the judgment of the investigator would make the patient inappropriate
             for entry into this study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Monash Health-Monash Medical Centre - Clayton</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3000 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>British Columbia Cancer Agency</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Sanofi</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Ozmosis Research Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess and compare the clinical benefit rate in patients with
      metastatic castrate-resistant prostate cancer and poor prognostic factors treated with
      cabazitaxel or novel hormonal agents (abiraterone or enzalutamide) as initial therapy, to
      determine which treatment is most active in this population. Clinical benefit rate is defined
      as PSA or measurable radiological response of any duration or stable disease for &gt; or equal
      to 12 weeks, in the absence of other indicators of progression.

      There is option to cross-over onto the other arm if the patient progresses.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02254785</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kim N Chi, MD</name>
      <address>British Columbia Cancer Agency</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Kim N Chi, MD</name>
      <address />
      <phone>604-877-6000</phone>
      <fax />
      <email>kchi@bccancer.bc.ca</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>